Texas Oncology and Aetna partnered to provide a practice-based program that reduced costs while maintaining adherence to treatment pathways and patient satisfaction in Medicare patients.
Bobby Daly, MD, MBA, and Ray D Page, DO, PhD, discuss the ramifications of clinical pathway vendor conflicts of interest and the potential issues of full transparency on the part of committee members.
A recent literature review analyzed the alternative payment models used in the real world and how they have affected the quality of oncology care.
Widespread use of alternative payment models may improve the quality of breast and colorectal cancer screening programs.
Experts at the ACCC 44th Annual Meeting & Cancer Center Business Summit identified some of the largest drivers of change and rapidly evolving initiatives in oncology care, including costs of care and precision medicine initiatives.
A recent study examined a potential association between system-level integration and longitudinal costs of cancer care.
Clinical pathways may require a deeper consideration of the patient experience in order to achieve the goals of the Triple Aim, according to Winston Wong, PharmD.
The NCCN has selected Envision's medical affairs platform to help manage proposals and investigator-initiated clinical trials in an effort to improve patient quality of life and reduce cancer-related deaths.
The ASCO Task Force assessed six national pathway vendors to compare their products against the ASCO criteria for high-quality clinical pathways.
A study to be presented at the 2018 ASCO Genitourinary Cancers Symposium applied the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate and enzalutamide in advanced prostate cancer.